- Proteins and Peptides
- Lysates and Cell Lines
MINNEAPOLIS, Minnesota [July 11, 2016] – Bio-Techne Corporation, a global life sciences company providing innovative biotechnology research tools and instruments for the academic, biotech, pharma and diagnostic communities announced today that its R&D Systems® and Novus Biologicals® brands are sponsors of the 2nd International Annual Antibody Validation Meeting, to be held at the University of Bath, UK, September 15-16, 2016. The meeting provides a forum for researchers from academia and industry to discuss reproducibility, best practices, challenges and standards in antibody validation techniques.
Birte Aggeler, Director of Antibody Development at Bio-Techne, will speak at the conference. She will be one of several industry representatives sharing examples of best practices in antibody development and manufacture. Dr. Aggeler will speak about the process of maintaining high quality antibody products from product concept to development to production that has been gained during Bio-Techne’s 20 years of producing antibody products.
Dr. Aggeler will present on how to choose the correct antigen for the desired applications as well as considerations when choosing a host species. In addition, Dr. Aggeler will present data related to antibody validation during the development phase of our products and discuss advantages of recombinant monoclonal antibodies compared to hybridoma-based monoclonal and polyclonal antibodies.
"Bio-Techne has a long-standing reputation in the industry for developing high-quality antibodies for our immunoassays. One example is our gold standard Quantikine® ELISA assays, which were developed and optimized for highly reproducible performance. Leading Researchers around the world rely on these assays to provide reproducible results and our Quantikine® ELISAs are now the most referenced in the industry" said Dr. Aggeler.
"I am looking forward to discussing validation best practices and hearing about new techniques and challenges in antibody-based research. Antibody validation continues to be a popular topic of discussion across academia and industry. One of the most crucial aspects of any development pipeline is using high-quality, well validated antibodies in every antibody-based application or assay," added Dr. Aggeler. "By sharing our findings and current ideas we are working toward agreement on accepted validation techniques. The Antibody Validation Meeting will also allow us to exchange ideas for developing scalable approaches going forward and to receive valuable feedback from our customers."
Bio-Techne is also proud to be involved in a number of global antibody validation and reproducibility initiatives including the Affinity Knockdown Binder Initiative, Cancer Reproducibility Project and the F1000 Research Antibody Validation Channel.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $452 million in net sales in fiscal 2015 and has approximately 1,500 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.
About R&D Systems
R&D Systems®, a Bio-Techne brand, has been serving the research community for over 35 years with quality reagents that enable life science research. It was one of the first companies to make cytokines commercially available in the late 1970s. Its product portfolio has expanded to become a world leader in immunoassays as well as a producer of antibodies, arrays, stem cell products, cell selection and other cell biology tools. For more information, visit www.rndsystems.com.
About Novus Biologicals
Novus Biologicals®, a Bio-Techne brand, accelerates scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies and proteins to the bioscience community. All of its products are 100% guaranteed to conform to the application claims listed on the datasheet. Novus Biologicals is committed to innovation and has formed and will continue to form ongoing partnerships with leading researchers. For more information visit www.novusbio.com.
Contact: Bryan Tinsley, VP of Marketing, Novus Biologicals
Phone: 303 730 1950
Fax: 303 730 1966